Overview
Cardiogen is a synthetic four-amino-acid peptide bioregulator developed specifically to target heart muscle (myocardium) tissue and cardiovascular cellular repair.
What problem it targets: It targets heart muscle fatigue, ischemic heart stress, age-related myocardial stiffness, high cardiovascular strain in athletes, and post-infarction tissue recovery.
What It Does
• Stimulates myocardial protein synthesis: Interacts with DNA in cardiac muscle cells (cardiomyocytes), stimulating the synthesis of structural proteins required for healthy heart contraction.
• Inhibits pathological cardiac fibrosis: Downregulates excess scar tissue and collagen deposition within the heart wall, preserving heart flexibility and ventricular compliance.
• Enhances myocardial resistance to hypoxia: Protects heart muscle cells from dying during periods of oxygen starvation and heavy cardiovascular exertion.
• Realistic expectations: Typically run in short 10- to 20-day cycles a few times per year. Designed to optimize cellular heart health and physical stamina over time rather than acting as an acute stimulant.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 20 mg (assumed vial strength) | 2 mL bacteriostatic water (requested mixing example) | 10 mg/mL = 10,000 micrograms/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Presentation
20 mg vial used for the mixing example. Other sizes exist. Confirm the actual peptide content and sequence on the batch documentation.
Protocol
Community protocols & cycle timing
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Common community cycle pattern | 10–20 consecutive days; a few courses per year with months between courses | Compound- and formulation-specific; see rows below | A shared cycle duration does not establish one shared dose. Oral labels may specify 30-day initial courses or 10-day maintenance courses. |
| Community-reported course | Daily for 20 days | 2 mg | Firsthand Reddit report: started before bed, reported elevated resting heart rate, then reported improvement after moving the timing earlier. Route not confirmed in the post. This is an anecdote, not a recommended regimen. |
Research study amounts
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Rat heart tissue culture | Exposure in an organ-culture experiment | 0.05 ng/mL | 2006 study; concentration in culture medium, not an injected or oral human dose. |
About these protocols
The community rows describe reported experience, not a standard or recommended human regimen. Product-label rows apply to the cited formulation; cell and animal rows describe research models. The 20 mg / 2 mL table is a concentration example using the requested assumptions. Solvent compatibility and stability are product-specific.
Handling & Stacking
- Bioregulators are often discussed as short 10–20-day courses, repeated a few times a year with months between courses, rather than continuous daily use.
- This describes a community cycle pattern, not one universal dose.
- Some finished oral products instead specify a 30-day course or 10-day maintenance course.
- Where users report subcutaneous administration, the abdomen or outer thigh are common subcutaneous sites.
- This does not establish an approved administration route for this compound.
- No compound-specific universal storage temperature or post-mixing stability period was verified.
- Use the supplier’s stability data for that formulation.
- Keep identity, lot, preparation date and final concentration traceable; a purity percentage alone does not establish sterility or stability.
- The named preparation is not established here as an approved treatment for its marketed goals.
- Approved alternatives depend on the diagnosed condition and cannot be assigned from an organ label alone.
